Focused On-demand Library for DNA polymerase delta catalytic subunit

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

3'-5' exodeoxyribonuclease; DNA polymerase subunit delta p125

Alternative UPACC:

P28340; Q8NER3; Q96H98


DNA polymerase delta catalytic subunit, also known as P28340, plays a pivotal role in high fidelity genome replication and repair, including lagging strand synthesis. It exhibits DNA polymerase and 3'- to 5'-exonuclease activities, crucial for maintaining genomic integrity. The protein operates in trimeric (Pol-delta3) and tetrameric (Pol-delta4) complexes, with its activity modulated by accessory proteins POLD2, POLD3, and POLD4.

Therapeutic significance:

The protein's involvement in Colorectal cancer 10 and Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome highlights its therapeutic significance. Understanding the role of DNA polymerase delta catalytic subunit could open doors to potential therapeutic strategies for these conditions, emphasizing the importance of targeted research in uncovering novel treatment avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.